Roland Schnell

Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial

Thomas Elter, Peter Borchmann, H. Schulz et al. · Journal of Clinical Oncology · 2005 · 212 citations

Medicine, Oncology, Pharmacotherapy +17

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

H. Schulz, U. Rehwald, Franck Morschhauser et al. · Blood · 2007 · 181 citations · Full text

Medicine, Immunology, Oncology +15

A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma

Andreas Engert, Volker Diehl, Roland Schnell et al. · Blood · 1997 · 141 citations · Full text

Life Sciences, Immunology, Oncology +11

A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo

Elke Pogge von Strandmann, Hinrich P. Hansen, Katrin S. Reiners et al. · Blood · 2005 · 139 citations

Life Sciences, Immunology, Oncology +17

A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

Roland Schnell, Oliver Staak, Peter Borchmann et al. · PubMed · 2002 · 136 citations

Medicine, Oncology, Pharmacology +16